neurocrine biosciences ingrezza

Why Neurocrine Biosciences, Inc.’s (NBIX) Stock Is Down 18.53%

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time to buy.

Hosted on MSN · 6h

Guggenheim cuts Neurocrine Bio. stock target to $163

Guggenheim maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but lowered the price target to $163 from $165. The adjustment follows the company's fourth-quarter sales report, which showed Ingrezza sales slightly below consensus estimates.

Business Insider · 8h

Neurocrine price target lowered to $163 from $165 at Guggenheim

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company

Benzinga.com · 3d

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth despite near-term challenges.

Hosted on MSN · 4h

UBS cuts Neurocrine Bio. stock target to $154, maintains Buy rating

UBS analyst Ashwani Verma adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $154 from the previous $176, while continuing to recommend the stock as a Buy. Currently trading at $118.

FiercePharma7h

With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Neurocrine Biosciences Reports Mixed Q4

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Seeking Alpha3d

Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force

Analysts raised concerns about the sustainability of INGREZZA’s growth trajectory and the competitive landscape. Neurocrine Biosciences enters 2025 with strong momentum from record-breaking 2024 ...

Neurocrine Biosciences Inc (NBIX) Q4 2024 Earnings Call Highlights: Record INGREZZA Growth and ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

Mirae Asset Global Investments Co. Ltd. Grows Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 21.8% in the fourth quarter, according to the company in its most ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results